Stargardt disease (STGD1) represents one of the major common causes of inherited irreversible visual loss. Due to its high phenotypic and genotypic heterogeneity, STGD1 is a complex disease to understand. Non-invasive imaging, biochemical, and genetic advances have led to substantial improvements in unveiling the disease processes and novel promising therapeutic landscapes have been proposed. This review recapitulates the mod-alities for monitoring patients with STGD1 and the therapeutic options currently under investigation for the different stages of the disease.
Monitoring and management of the patient with stargardt disease / Cicinelli, M. V.; Battista, M.; Starace, V.; Battaglia Parodi, M.; Bandello, F.. - In: CLINICAL OPTOMETRY. - ISSN 1179-2752. - 11:(2019), pp. 151-165. [10.2147/OPTO.S226595]
Monitoring and management of the patient with stargardt disease
Cicinelli M. V.;Battista M.;Starace V.;Battaglia Parodi M.;Bandello F.
2019-01-01
Abstract
Stargardt disease (STGD1) represents one of the major common causes of inherited irreversible visual loss. Due to its high phenotypic and genotypic heterogeneity, STGD1 is a complex disease to understand. Non-invasive imaging, biochemical, and genetic advances have led to substantial improvements in unveiling the disease processes and novel promising therapeutic landscapes have been proposed. This review recapitulates the mod-alities for monitoring patients with STGD1 and the therapeutic options currently under investigation for the different stages of the disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
